

1 Integrated transcriptomic, proteomic and epigenomic 2 analysis of *Plasmodium vivax* salivary-gland sporozoites.

3
4 Vivax Sporozoite Consortium* (Ivo Muller^{1,2,3}, Aaron R. Jex^{1,3,4}, Stefan H. I. Kappe⁵,
5 Sebastian A. Mikolajczak⁵, Jetsumon Sattabongkot⁷, Rapatbhorn Patrapuvich⁶, Scott
6 Lindner⁸, Erika L. Flannery⁵, Cristian Koepfli¹, Brendan Ansell⁴, Anita Lerch¹, Kristian E.
7 Swearingen⁵, Robert L. Moritz⁹, Michaela Petter^{10,11}, Michael Duffy¹⁰, Vorada Chuenchob⁵).

8 *Group authorship – all authors are equal contributors (order per author contributions section below).
9

- 10 1. Population Health and Immunity Division, The Walter and Eliza Hall Institute for Medical Research, 1G Royal Parade,
11 Parkville, Victoria, 3052, Australia.
- 12 2. Malaria: Parasites & Hosts Unit, Institut Pasteur, 28 Rue de Dr. Roux, 75015, Paris, France.
- 13 3. Department of Global Health, University of Washington, Seattle, WA 98195, USA.
- 14 4. Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Corner of Park and Flemington Road,
15 Parkville, Victoria, 3010, Australia.
- 16 5. Center for Infectious Disease Research, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109, USA;
- 17 6. Department of Global Health, University of Washington, Seattle, WA 98195, USA.
- 18 7. Mahidol Vivax Research Center, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.
- 19 8. Department of Biochemistry and Molecular Biology, Center for Malaria Research, Pennsylvania State University, University
20 Park, PA 16802, USA.
- 21 9. Institute for Systems Biology, Seattle, WA, 98109, USA.
- 22 10. Department of Medicine Royal Melbourne Hospital, The Peter Doherty Institute, The University of Melbourne, 792
23 Elizabeth Street, Melbourne, Victoria 3000, Australia.
- 24 11. Institute of Microbiology, University Hospital Erlangen, Erlangen 91054, Germany

25 26 Abstract

27 **Background:** *Plasmodium vivax* is the key obstacle to malaria elimination in Asia and Latin
28 America, largely attributed to its ability to form resilient ‘hypnozoites’ (sleeper-cells) in the
29 host liver that escape treatment and cause relapsing infections. The decision to form
30 hypnozoite is made early in the liver infection and may already be set in sporozoites prior to
31 invasion. To better understand these early stages of infection, and the potential mechanisms
32 through which the development may be pre-programmed, we undertook a comprehensive
33 transcriptomic, proteomic and histone epigenetic characterization of *P. vivax* sporozoites.
34

35 **Results:** Our study highlights the loading of the salivary-gland sporozoite with proteins
36 required for cell traversal and invasion and transcripts for infection of and development
37 within hepatocytes. We characterise histone epigenetic modifications in the *P. vivax*
38 sporozoite and explore their role in regulating transcription. This work shows a close
39 correlation between H3K9ac marks and transcriptional activity, with H3K4me3 and
40 H3K9me3 appearing to act as general markers of euchromatin and heterochromatin
41 respectively. We also identify the remarkable transcriptional silence in the (sub)telomeres and
42 discuss potential roles of AP2 transcription factors, specifically ApiAP2-SP and L in
43 regulating this stage.
44

45 **Conclusions:** Collectively, these data indicate the sporozoite as a tightly programmed stage
46 primed to infect the human host and identifies key targets to be further explored in liver stage
47 models.
48

49 Background

50 Malaria is among the most significant infectious diseases impacting humans globally, with
51 3.3 billion people at risk of infection, 381 million suspected clinical cases and up to ~660,000
52 deaths attributed to malaria globally in 2014 [1]. Two major parasite species contribute to the
53 vast majority of human malaria, *Plasmodium falciparum* and *P. vivax*. Historically, *P.*
54 *falciparum* has attracted the majority of global attention, due to its higher contribution to
55 morbidity and mortality. However, *P. vivax* is broadly distributed, more pathogenic than
56 previously thought, and is recognised as the key obstacle to malaria elimination in the Asia-
57 Pacific and Americas [2]. Unlike *P. falciparum*, *P. vivax* can establish long-lasting ‘sleeper-
58 cells’ (= hypnozoites) in the host liver that emerge weeks, months or years after the primary

59 infection (= relapsing malaria) [3]. Primaquine is the only approved drug that prevents
60 relapse. However, the short half-life, long dosage regimens and incompatibility of primaquine
61 with glucose-6-phosphate-dehydrogenase deficiency (which requires pre-screening of
62 recipients [4]) makes it unsuitable for widespread use. As a consequence, *P. vivax* is
63 overtaking *P. falciparum* as the primary cause of malaria in a number of co-endemic regions
64 [5]. Developing new tools to diagnose, treat and/or prevent hypnozoite infections is
65 considered one of the highest priorities in the malaria elimination research agenda [6].

66 When *Plasmodium* sporozoites are deposited by an infected mosquito, they likely
67 traverse the skin cells, enter the blood-stream and are trafficked to the host liver, as has been
68 shown in rodent malaria parasites [7]. Upon reaching the liver, sporozoites traverse Kupffer
69 and endothelial cells to reach the parenchyma, moving through several hepatocytes before
70 invading a final hepatocyte suitable for liver stage development [7, 8]. Within hepatocytes,
71 these parasites replicate, and undergo further development and differentiation to produce tens
72 of thousands of merozoites that emerge from the liver and infect red blood cells. However, *P.*
73 *vivax* sporozoites are able to commit to two distinct developmental fates within the
74 hepatocyte: they either immediately continue development as replicating schizonts and
75 establish a blood infection, or delay replication and persist as hypnozoites. Regulation of this
76 major development fate decision is not understood and this represents a key gap in current
77 knowledge of *P. vivax* biology and control.

78 The sporozoites' journey from skin deposition to hepatocytes takes less than a few
79 minutes [9]. It has been hypothesized that *P. vivax* sporozoites exist within an inoculum as
80 replicating 'tachysporozoites' and relapsing 'bradysporozoites' [10] and that these
81 subpopulations may have distinct a developmental fate as schizont or hypnozoites, thus
82 contributing to their relapse phenotype [10-12]. This observation is supported by the stability
83 of different hypnozoite phenotypes in *P. vivax* infections of liver-chimeric mouse models
84 [13]. Sporozoites prepare for mammalian host infection while still residing in the mosquito
85 salivary glands. Studies using rodent malaria parasites have identified genes [14], that are
86 transcribed in sporozoites but translationally repressed (i.e., present as transcript but un- or
87 under-represented as protein), via RNA-binding proteins [15], and ready for just-in-time
88 translation after the parasites infection of the mammalian host [13, 16]. Translational
89 repression (i.e., the blocking of translation of present and retained transcripts) and other
90 mechanisms of epigenetic control may contribute to the *P. vivax* sporozoite fate decision and
91 hypnozoite formation, persistence and activation. Supporting this hypothesis, histone
92 methyltransferase inhibitors stimulate increased activation of *Plasmodium cynomolgi*
93 hypnozoites in macaque hepatocytes [17, 18]. Epigenetic control of stage development is
94 further evidenced in *Plasmodium* through chromatin structure controlling expression of
95 PfAP2-G, a specific transcription factor that, in turn, regulates gametocyte (dimorphic sexual
96 stages) development in blood-stages [19]. It is well documented that *P. vivax* hypnozoite
97 activation patterns stratify with climate and geography [11] and recent modelling suggests
98 transmission potential selects for hypnozoite phenotype [20]. Clearly the ability for *P. vivax*
99 to dynamically regulate hypnozoite formation and relapse phenotypes in response to high or
100 low transmission periods in different climate conditions would confer a significant
101 evolutionary advantage.

102 Unfortunately, despite recent advances [21] current approaches for *in vitro P. vivax*
103 culture do not support routine maintenance in the laboratory and tools to directly perturb gene
104 function are not established. This renders studies on *P. vivax*, particularly its sporozoites and
105 liver stages, exceedingly difficult. Although *in-vitro* liver stage assays and humanised mouse
106 models are being developed [13], they cannot yet support 'omics analysis of *P. vivax* liver
107 stage dormancy. Recent characterization [22] of liver-stage (hypnozoites and schizonts) of *P.*
108 *cynomolgi* (a related and relapsing parasite in macaques) provides valuable insight, but
109 investigations in *P. vivax* directly are clearly needed. The systems analysis of *P. vivax*
110 sporozoites that reside in the mosquito salivary glands and are poised for transmission and
111 liver infection offer a key opportunity to gain insight into *P. vivax* infection. To date, such
112 characterization of *Plasmodium vivax* sporozoites is limited [23], and only one recent study,
113 of *P. falciparum* [24], has undertaken exploration of epigenetic regulation in sporozoites of

114 any *Plasmodium* species. Here, we present a detailed characterization of the *P. vivax*
115 sporozoite transcriptome, proteome and epigenome and use these data to better understand
116 this key infective stage and the role of sporozoite programming in invasion and infection of
117 the human host, and development within the host liver.

118

119 **Results and Discussion**

120 We quantified transcript abundance for 5,714 *P. vivax* genes (4,991 with a mean transcript per
121 million (TPM) count ≥ 1.0) at a mean estimated abundance of 175.1 TPM (Additional File 1:
122 Figure S1 and Additional File 2: Table S1) for *P. vivax* sporozoites isolated from *Anopheles*
123 *dirus* salivary glands using the recently completed *P. vivax* P01 assembly and gene models
124 (see methods). For ease of reference, where one-to-one orthologs are established between the
125 P01 and previous *P. vivax* (Sall) reference, we use the Sall gene names in text (both the P01
126 and Sall gene names are provided for all genes in the supplementary information). Mosquito
127 infections were generated by membrane feeding of blood samples taken from *P. vivax*
128 infected patients in western Thailand ($n = 9$). Among the most highly transcribed genes in the
129 infectious sporozoite stage are *csp* (circumsporozoite protein), five *etramps* (early transcribed
130 membrane proteins), including *uis3* (up-regulated in infective sporozoites), *uis4* and *lsap-1*
131 (liver stage associated protein 1), a variety of genes involved in cell transversal and initiation
132 of invasion, including *celtos* (cell traversal protein for ookinetes and sporozoites), *gest*
133 (gamete egress and sporozoite traversal protein), *spect1* (sporozoite protein essential for cell
134 traversal) and *siap-1* (sporozoite invasion associated protein), and genes associated with
135 translational repression (*alba1*, *alba4* and *Puf2*). Collectively, these genes account for $>1/3^{\text{rd}}$
136 of all transcription in the sporozoite. We found moderate agreement ($R^2 = 0.35$; Additional
137 File 1: Figure S2) between our RNA-seq data and previous microarray data for *P. vivax*
138 sporozoites [23]. Improved transcript detection and quantitation is expected with the
139 improved technical resolution of RNA-seq over microarray. Supporting this, we find higher
140 correlation between RNA-seq data from *P. vivax* and *P. falciparum* (single replicate
141 sequenced herein for comparative purposes) sporozoite datasets ($R^2 = 0.42$), compared to
142 either species relative to published microarray data (Additional File 1: Figure S2). Although
143 microarray supports the high transcription in sporozoites of genes such as *uis4*, *csp*, *celtos* and
144 several other *etramps*, 27% and 16% of the most abundant 1% of transcribed genes in our
145 sporozoite RNA-seq data are absent from the top decile or quartile respectively in the existing
146 *P. vivax* sporozoite microarray data [23]. Among these are genes involved in early
147 invasion/hepatocyte development, such as *lsap-1*, *celtos*, *gest* and *siap-1*, or translational
148 repression (e.g., *alba-1* and *alba-4*); orthologs of these genes are also in the top percentile of
149 transcripts in RNA-seq (see [24] and Additional File 2: Table S2) and (see [25] and
150 Additional File 2: Table S3) and previous microarray data [26, 27] for *P. falciparum* and *P.*
151 *yoelii* sporozoites respectively, suggesting many are indeed more abundant than previously
152 characterized.

153

154 **Transcription in *P. vivax* relative to other plasmodia**

155 To gain insight into species-specific aspects of the *P. vivax* transcriptome, we qualitatively
156 compared these data with available data from *P. falciparum* and *P. yoelii* sporozoites (single
157 replicate only) for 4,220 and 4,067 single-copy orthologs (SCO) (transcribed at ≥ 1 TPM in *P.*
158 *vivax* infectious sporozoites) shared with *P. falciparum* (Additional File 2: Table S3) and with
159 both *P. falciparum* and *P. yoelii* (Additional File 2: Table S4) respectively. Genes highly
160 transcribed in salivary-gland sporozoites of all three species include *celtos*, *gest*, *trap*, *siap1*,
161 *spect1* and *puf2*. There are 696 *P. vivax* genes shared as orthologs between *P. vivax* P01 and
162 *P. vivax* Sall lacking a defined SCO in *P. falciparum* or *P. yoelii* transcribed at a mean of ≥ 1
163 TPM in *P. vivax* salivary-gland sporozoites (Additional File 2: Table S5). Prominent among
164 these are *vir* ($n=25$) and *Pv-fam* (41 fam-e, 16 fam-b, 14 fam-a, 8 fam-d and 3 fam-h) genes,
165 as well as, hypothetical proteins or proteins of unknown function ($n=212$) and, interestingly, a
166 number of ‘merozoite surface protein’ 3 and 7 homologs ($n=5$ of each). Both *msp3* and *msp7*
167 have undergone significant expansion in *P. vivax* relative to *P. falciparum* and *P. yoelii* [28]

168 and may have repurposed functions in sporozoites. In addition, there are 69 *P. vivax* P01
169 genes lacking a defined ortholog in *P. vivax* Sal1, *P. falciparum* or *P. yoelli* transcribed at ≥ 1
170 TPM in infectious *P. vivax* sporozoites; most of which are *Plasmodium* interspersed repeat
171 (PIR) genes [28] found in telomeric regions of the P01 assembly and likely absent from the
172 Sal1 assembly but present in the Sal1 genome.

173

174 ***P. vivax* sporozoite transcriptional enrichment**

175 To comprehensively identify sporozoite enriched transcripts, we compared the *P. vivax*
176 sporozoite transcriptome (Additional File 2: Table S6) to RNA-seq data for *P. vivax* blood-
177 stages [29] (the only other RNA-seq data presently available for *P. vivax*; Fig. 1 and
178 Additional File 1: Figures S3-5). We identified 1,672 up (Additional File 2: Table S7) and
179 1,958 down-regulated (Additional File 2: Table S8) transcripts (FDR ≤ 0.05 ; minimum 2-fold
180 change in Counts per Million (CPM)) and next explored patterns among these differentially
181 transcribed genes (DTGs) by protein family (Fig. 1C and Additional File 2: Table S9) and
182 Gene Ontology (GO) classifications (Additional File 2: Table S10). RNA recognition motifs
183 (RRM-1 and RRM-6) and helicase domains (Helicase-C and DEAD box helicases) are over-
184 represented (p-value < 0.05) among sporozoite-enriched transcripts, consistent with
185 translational repression through ribonucleoprotein (RNP) granules [30]. Transcripts encoding
186 nucleic acid binding domains, such as bromodomains (PF00439; which can also bind lysine-
187 acetylated proteins), zinc fingers (PF13923) and EF hand domains (PF13499) are also
188 enriched in sporozoites. Included among these proteins are a putative ApiAP2 transcription
189 factor (PVX_083040) and a homologue of the *Drosophila* zinc-binding protein ‘Yippee’
190 (PVX_099695). Thrombospondin-1 like repeats (TSR: PF00090) and von Willebrand factor
191 type A domains (PF00092) are enriched in sporozoites as well. In sporozoites, *P. falciparum*
192 genes enriched in TSR domains are important in invasion of the mosquito salivary gland (e.g.,
193 *trap*) and secretory vesicles released by sporozoites upon entering the vertebrate host (e.g.,
194 *msp*) [31]. By comparison, genes up-regulated in blood-stages are enriched for *vir* gene
195 domains (PF09687 and PF05796), Tryptophan-Threonine-rich *Plasmodium* antigens
196 (PF12319; which are associated with merozoites [32]), markers of cell-division
197 (PF02493), [33] protein production/degradation (PF00112, PF10584, PF00152, PF09688 and
198 PF00227) and ATP metabolism (PF08238 and PF12774). 47 of the 343 transcripts unique to
199 *P. vivax* sporozoites relative to *P. falciparum* or *P. yoelli* are enriched in sporozoites
200 compared to *P. vivax* blood stages. Nine of these are in the top decile of transcription, and
201 include a Pv-fam-e (PVX_089880), a Pf-fam-b homolog (PVX_001710) and 7 proteins of
202 unknown function. A further nine have an ortholog in *P. cynomolgi* (which also forms
203 hypnozoites) but not the closely related *P. knowlesi* (which does not form hypnozoites) and
204 include ‘*msp7*’-like (PVX_082685, PVX_082650 and PVX_082670) and ‘*msp3*’-like
205 (PVX_097705) and Pv-fam-e genes (PVX_001100, PVX_089860 and PVX_089810), a
206 serine-threonine protein kinase (PVX_081395) and a RecQ1 helicase homolog
207 (PVX_099345). Notably, the *P. cynomolgi* ortholog of PVX_081395, PCYB_021650, is
208 transcriptionally enriched in hypnozoites relative to replicating schizonts [22], indicating a
209 target of significant interest when considering hypnozoite formation and/or biology.

210

211 **Translational repression machinery**

212 In *Plasmodium*, translational repression regulates key life-cycle transitions coinciding with
213 switching between the mosquito and the mammalian host (either as sporozoites or
214 gametocytes) [30]. For example, although *uis4* is the most abundant transcript in the
215 infectious sporozoite ([23, 27]; Additional File 2: Table S1), UIS4 is translationally repressed
216 in this stage [15] and only expressed after hepatocyte invasion [34]. In sporozoites, it is
217 thought that PUF2 binds to mRNA transcripts and prevents their translation [25], and SAPI
218 stabilises the repressed transcripts and prevents their degradation [34]. Consistent with this,
219 *Puf2* and *SAPI1* are among the more abundant *P. vivax* transcripts enriched in the sporozoite
220 relative to blood-stages. Indeed, *Puf2* is among the top percentile of transcripts in infectious
221 sporozoites. However, our data implicate other genes, many already known to be involved in
222 translational repression in other *Plasmodium* stages and other protists [30], that may act in *P.*

223 *vivax* sporozoites. Notable among these are *alba-2* and *alba-4*, both of which are among the
224 top 2% of genes transcribed in sporozoites and ~14 to 20-fold more highly transcribed in
225 sporozoites relative to blood-stages. In addition, *P. vivax* sporozoites are enriched for genes
226 encoding RRM-6 RNA helicase domains. Intriguing among these genes are HoMu (homolog
227 of Musashi) and ptbp (polypyrimidine tract binding protein). Musashi is a master regulator of
228 eukaryotic stem cell differentiation through translational repression [35] and HoMu localizes
229 with DOZI and CITH in *Plasmodium* gametocytes [36]. PTBP is linked to mRNA stability,
230 splice regulation and translational initiation [37] and may perform a complementary role to
231 SAP1.

232

233 **Translational repression in *P. vivax* sporozoites**

234 More than 700 genes have been identified as being translationally repressed in *Plasmodium*
235 *berghei* ('rodent malaria') gametocytes based on DOZI pulldowns [38]. In contrast,
236 translationally repressed genes have not been characterized in sporozoites in a comprehensive
237 way. As a step in addressing this, we analysed the *P. vivax* sporozoite proteome (Additional
238 File 1: Figure S6 and Additional File 2: Table S11) by mass spectrometry and identified
239 peptide signals for 2,640 proteins. Among the most highly expressed proteins in sporozoites
240 were those associated with the apical complex (AMA1, GAMA, RON12, RON3, RON5),
241 motility / cell traversal (MYOSIN A, PLP1, TRAP, SIAP1, GEST, SPECT1, CELTOS) and
242 the inner membrane complex (ISP1/3, IMC1a, e, g, h, m and k), which has a key role in
243 motility and invasion [39]. We identified 2,402 *P. vivax* genes transcribed in the sporozoite
244 (TPKM > 1) for which no protein expression was detected. In considering genes that may be
245 translational repressed (i.e., transcribed but not translated) in the *P. vivax* sporozoite, we
246 confine our observations to those transcripts representing the top decile of transcript
247 abundance to ensure their lack of detection as proteins was not due to limitations in the
248 detection sensitivity of the proteomic dataset. Notably, ~1/3rd of transcripts in the top decile
249 of transcriptional abundance (n = 173 of 558) in *P. vivax* sporozoites were not detectable as
250 peptides in multiple replicates (Additional File 2: Table S12). Of these 173 putatively
251 repressed transcripts, 156 and 154 have orthologs in *P. falciparum* and *P. yoelii* respectively,
252 with 89 and 118 of these also not detected as proteins in *P. falciparum* and *P. yoelii* salivary-
253 gland sporozoites [40] despite being identified as transcribed in these stages (see [24, 25];
254 Additional File 2: Tables S2-4). In addition, a number of genes (e.g., *uis4*) are expressed in
255 infectious *P. vivax* sporozoites at levels many fold lower than their transcription might
256 indicate (bottom quartile of protein expression, compared with top decile of transcript
257 abundance). While each putatively repressed transcript will require validation, this system
258 level approach is supported by immunofluorescent imaging (Additional File 1: Figure S7) of
259 UIS4 and LISP1 (one known and one proposed here as translationally repressed in *P. vivax*
260 sporozoites) relative to TRAP and BiP (which are both transcribed and expressed as protein in
261 the *P. vivax* sporozoite; Additional File 2: Table S12).

262

263 *Development within the host hepatocyte*

264 Following cell traversal and hepatocyte invasion, *P. vivax* sporozoites establish their
265 intracellular niche, which includes modification of the parasitophorous vacuole membrane
266 (PVM) and the parasite then proceeds to replicate as a liver stage. UIS3 and UIS4 are resident
267 PVM-proteins and are the best characterized proteins under translational repression by
268 Puf2/SAP1 in infectious sporozoites [41], both of which are essential for liver stage
269 development [14]. In the present study, *uis4* represents 18.8% of transcripts but just 0.06% of
270 proteins in the sporozoites. Similarly, *uis3* is the 7th most abundant transcript in sporozoites,
271 but represented only by a single peptide count in one proteomic replicate. In addition to *uis3*
272 and *uis4*, genes involved in liver stage development and under apparent translational
273 repression in the *P. vivax* sporozoites include *lsapl* (liver stage associated protein 1), *zipco*
274 (ZIP domain-containing protein), several other *etramps* (PVX_118680, PVX_003565,
275 PVX_088870 and PVX_086915), *pv1* (parasitophorous vacuole protein 1) and *lisp1* and *lisp2*
276 (PVX_085550 and PVX_000975). The *lisp1* gene is an intriguing find, and may have an
277 altered role in *P. vivax* liver stages (Additional File 1: Figure S7). In *P. berghei*, *lisp1* is

278 essential for rupture of the PVM during liver stage development allowing release of the
279 merozoite into the host blood stream. *Pv-lisp1* is ~350-fold and ~1,350-fold more highly
280 transcribed in *P. vivax* sporozoites compared to sporozoites of either *P. falciparum* or *P.*
281 *yoelli* (see Additional File 2: Table S4). Also notable among translationally repressed genes in
282 sporozoites is a putative ‘Yippee’ homolog (PVX_099695). Yippee is a DNA-binding protein
283 that, in humans (YPEL3), suppresses cell growth [42]. Its specific function in *Plasmodium*,
284 either in parasite development or on the host interactions, is not yet known. However, that
285 Yippee-like proteins suppress cell growth/division and appear to be regulated through histone
286 acetylation [43] is intriguing in the context of a potential role in *P. vivax* hypnozoite
287 developmental arrest.

288 The *P. vivax* ortholog (PVP01_1016100; no corresponding ortholog is identified in
289 the *P. vivax* Sal1 assembly) of the *P. cynomolgi* AP2 transcription factor, PCYB_102390,
290 which was recently designated AP2-Q (i.e., ‘quiescent’) due to its enriched transcription in *P.*
291 *cynomolgi* hypnozoites [22], is also detectable as transcripts but not proteins in *P. vivax*
292 sporozoites. This may support a specific role for this transcription factor in hypnozoites.
293 However, as Pv-AP2-Q is transcribed at an abundance (~50 TPM) at or below which ~≥50%
294 of *P. vivax* genes are detectable as transcripts but not as proteins, the lack of detected AP2-Q
295 protein could as likely result from the detection sensitivity of the proteomics data-set as from
296 translation repression. Furthermore, while AP2-Q is proposed in *P. cynomolgi* as a possible
297 hypnozoite marker in part due to its presence in *P. cynomolgi*, *P. vivax* and *P. ovale* (all of
298 which generate hypnozoites) and reported absence from other *Plasmodium* species [22].
299 However, orthologs of this gene are also identified in PlasmoDB for several non-hypnozoite
300 producing *Plasmodium* species, such as *P. knowlesi*, *P. gallinaceum* and *P. inui*, raising
301 questions in regard to its function in these parasite species.

302 Lastly, while *Plasmodium* species lack a classical Golgi body, some genes (e.g., *golgi*
303 *reassembly stacking protein*) functioning in protein transport between the Golgi body and the
304 endoplasmic reticulum have been repurposed for vesicular transport and protein secretion
305 during invasion [44]. Noting this, several homologs of genes associated with cycling of
306 proteins between the Golgi body and the ER in other eukaryotes, including COPI-associated
307 protein (PVX_100850), a putative STF2 (PVX_116780) and Got1 (PVX_090050) appear
308 under translational repression in *P. vivax* sporozoites. Interestingly, in liver cells, the
309 membrane of the parasitophorous vacuole, in which *Plasmodium* resides, often associates
310 with the host cell ER and Golgi apparatus and may exploit this association to hijack host
311 secretory pathways [45]. This may represent a key mechanism underpinning development in
312 hepatocytes meriting further study.

313

314 *Apoptosis-inhibition*

315 Also notable among genes apparently translationally repressed in sporozoites are two putative
316 Bax1 (Bcl-2 associated X protein) inhibitors (PVX_117470 and PVX_101315). Bax1
317 dimerizes with Bcl-2 to promote intrinsic apoptosis, leading to destruction of the
318 mitochondrial membrane, caspase release and cell death. Bax1 inhibitor is a component of the
319 cell stress response to prevent Bax1 from prematurely triggering cell death. When Bax1 is
320 blocked, Bcl-2 switches from a cell-death to a pro-survival/anti-apoptotic role [46].
321 Intriguingly, specific suppression of mitochondrial-induced apoptosis has been demonstrated
322 in liver-cells infected with *P. yoelii* [47] and this anti-apoptotic signal is blocked by Bcl-2
323 family inhibitors [48]. Orthologs of both *P. vivax* encoded Bax1 inhibitors are found in all
324 *Plasmodium* species, suggesting a conserved function across the genus. Nonetheless, it is
325 attractive to contemplate a potential role for these genes in promoting survival of host
326 hepatocytes following the initial parasite invasion. Notably, the *P. cynomolgi* orthology of
327 PVX_101315, PCYB_147290, is ~2-fold enriched in transcript abundance in schizonts
328 compared to hypnozoites, which may indicate a role in repressing hepatocyte cell death
329 during parasite replication rather than extending its life-span during parasite dormancy. This
330 is to be explored.

331

332 **Potential binding motif for Pv-Puf2**

333 Research in *Toxoplasma gondii*, has identified a repetitive UGU motif in coding regions of
334 translationally repressed genes bound by *Tg*-Puf2 [49] and, presumably, mediating repression.
335 A similar UGU motif has been identified in the 3'UTR of *P. falciparum* transcripts (e.g.,
336 pfs25 and pfs28) and shown to bind PfPUF2 leading to their translational repression [50]. The
337 binding motif for *Pv*-PUF2 has not been described. We found one motif (AGAT[TAC]G;
338 Additional File 1: Figure S8) over-represented in coding regions of putatively repressed
339 sporozoite transcripts relative to similarly highly transcribed but also translated genes e-value:
340 $1.9e^{-9}$). We note the complementarity between AGAT and UGUA, however no over-
341 represented motifs were detected in the 3'UTRs of these genes. Intriguingly, translational
342 repression of *uis4* in *P. berghei* does not require the UTR [15]. It may be that the location of
343 the *Puf2*-binding motif is somewhat flexible in *Plasmodium* and other apicomplexan
344 species. We also identified a similarly over-represented motif ([GT]CGTC[CT]) within
345 500bp upstream of putatively repressed genes (p-value: $2.2e^{-9}$). It is possible this motif is a
346 binding site for an as yet unattributed transcription factor co-ordinating genes destined for
347 translational repression in the sporozoite. This motif is comparable to the [AG]C[AG]TGC
348 motif identified for Pf-AP2-Sp [24], a transcription factor that is required for sporozoite
349 development in *P. berghei* [51], and transcriptionally enriched in *P. falciparum* [24] and *P.*
350 *vivax* (Additional File 2: Table S7) sporozoites relative to oocysts or blood stages
351 respectively.

352

353 **Histone modifications in *P. vivax* sporozoites**

354 No epigenetic data are currently available for any *P. vivax* life-cycle stage. Studies of *P.*
355 *falciparum* blood-stages have identified the importance of histone modifications as a primary
356 epigenetic regulator [52, 53] and characterized key markers of heterochromatin (H3K9me³)
357 and euchromatin/transcriptional activation (H3K4me³ and H3K9ac). Recently, these marks
358 have been explored with the maturation of *P. falciparum* sporozoites in the mosquito [24].
359 Here, we characterize these marks in *P. vivax* sporozoites and assess their relationship to
360 transcript abundance. Clearly this is of particular interest as a potential mechanism for
361 dynamic regulation of sporozoite development in human hepatocytes. We identified 1,506,
362 1,999 and 5,262 ChIP-seq peaks stably represented in multiple *P. vivax* sporozoite replicates
363 and associated with H3K9me³, H3K9ac and H3K4me³ histone marks respectively (Fig. 2).
364 Peak width, spacing and stability differed with histone mark type (Additional File 1: Figures
365 S9 and S10). H3K4me³ peaks were significantly broader (mean width: 1,985 bp) than H3K9
366 peaks, and covered the greatest breadth of the genome; 36.0% of all bases were stably
367 associated with H3K4me³ marks. This mark was also most stable among replicates, with just
368 ~16% of bases associated with an H3K4me³ not supported by more than one biological
369 replicate. By comparison H3K9me³ marks were narrowest (mean width: 796 bp) and least
370 stable, with 46% of bases associated with this mark supported by just one replicate.
371 Consistent with observations in *P. falciparum* H3K9me³ 'heterochromatin' marks primarily
372 clustered in telomeric and subtelomeric regions (Additional File 1: Figure S11). In contrast,
373 the 'euchromatin' / transcriptionally open histone marks, H3K4me³ and H3K9ac clustered
374 around genic regions and did not overlap with regions under H3K9me³ suppression. Both
375 H3K9me³ and H3K4me³ marks were reasonably uniformly distributed (mean peak spacing
376 ~500bp for each) within their respective regions of the genome. In contrast, H3K9ac peaks
377 were spaced farther apart (mean: ~2kb), but also with a greater variability in spacing (likely
378 reflecting their association with promoter regions [54]). The instability of H3K9me³ may
379 reflect its use in *Plasmodium* for regulating variegated expression of contingency genes from
380 multigene families whose members have overlapping and redundant functions [55] and confer
381 phenotypic plasticity [56].

382

383 *Genes under histone regulation*

384 We explored an association between these histone marks and the transcriptional behaviour of
385 protein coding genes (Fig. 2 and Additional File 2: Tables S13-17). 485 coding genes stably
386 intersected with an H3K9me³ mark; all are located near the ends of the chromosomal
387 scaffolds (i.e., are (sub)telomeric). On average, these genes are transcribed at ~30 fold lower

388 levels (mean <3 TPKMs) than genes not stably intersected by H3K9me³ marks. These data
389 clearly support the function of this mark in transcriptional silencing. This is largely consistent
390 with observations in *P. falciparum* sporozoites [24], however, we observe no instances of
391 genes that are stably marked by H3K9me³ and moderately or highly transcribed regardless.
392 Whether this relates to differences in epigenetic control between the species is not clear. We
393 note that (sub)telomeric genes are overall transcriptionally silent in *P. vivax* sporozoites
394 relative to blood-stages (Fig. 2a and 2b and Additional File 2: Tables S18-20). Consistent
395 with observations in *P. falciparum* [52], the bulk of these genes include complex protein
396 families, such as *vir* and *Pv-fam* genes, which function primarily in blood-stages. Also
397 notable among the genes are several reticulocyte-binding proteins, including RBP2, 2a, 2b
398 and 2c. Strikingly, we find no exceptions to this trend in our data, indicating the
399 (sub)telomeres are remarkably transcriptionally silent in the sporozoite stage. By comparison,
400 H3K4me³ marks are stably associated with the Transcription Start Site (TSS) and/or 5' UTRs
401 of 3,677 genes. We also identified 1,284 coding genes stably associated with an H3K9ac
402 mark within 1kb of the TSS, with 179 of these genes stably marked also by H3K4me³. The
403 average transcription of these genes is 116, 180 and 199 TPKMs respectively (39, 60 and 66-
404 fold higher than H3K9me³ marked genes). These data support the role of these marks in
405 transcriptional activation, the lower abundance of H3K4me³ marker, compared with H3K9ac
406 or H3K9ac and H3K4me³ marked genes suggest these marks work synergistically and that
407 H3K9ac is possibly the better single mark indicator of transcriptional activity in *P. vivax*. This
408 is consistent with recent observations in *P. falciparum* sporozoites [24].

409 Interestingly, H3K9ac-marked genes ranged in transcriptional activity from the most
410 abundantly transcribed genes to many in the lower 50% and even lowest decile of
411 transcription. This suggests more contributes to transcriptional activation in *P. vivax* than,
412 simply, gene accessibility through chromatin regulation. Specific activation by a transcription
413 factor (e.g., ApiAP2s [57]) is the most obvious candidate. To explore this, we compared
414 upstream regions (within 1kb of the TSS or up to the 3' end of the next gene upstream,
415 whichever was less) of highly (top 10%) and lowly (bottom 10%) transcribed H3K9ac
416 marked genes for over-represented sequence motifs that might coincide with known ApiAP2
417 transcription factor binding sites [58]. We identified these based on the location of the nearest
418 stable H3K9ac peak relative to the transcription start site for each gene (Additional File 1:
419 Figure S12). In most instances, these peaks were within 100bp of the TSS and, consistent
420 with data from *P. falciparum* [54], *P. vivax* promoters appear to be no more than a few
421 hundred to a maximum of 1000 bp upstream of the TSS. Exploring these regions, we
422 identified two over-represented motifs: TGTACMA (e-value $2.7e^{-2}$) and ATATTTH (e-value
423 $3.3e^{-3}$) (Fig. 2D). TGTAC is consistent with the known binding site for *Pf*-AP2-G, which
424 regulates sexual differentiation in gametocytes [59], but its *P. vivax* ortholog (PVX_123760)
425 is neither highly transcribed nor expressed in sporozoites. It may be that some genes encoding
426 this domain are active in both sporozoites and gametocytes, but regulated by different
427 mechanisms in each stage. Alternatively, this motif may represent a binding site for another,
428 as yet uncharacterized transcription factor (e.g., PVX_083040). ATATTTH is similar to the
429 binding motif for *Pf*-AP2-L (AATTTCC), a transcription factor that is important for liver
430 stage development in *P. berghei* [60]. In contrast to AP2-G, *Pv*-AP2-L (PVX_081180) is in
431 the top 10% of transcription and expression in *P. vivax* sporozoites and enriched relative to
432 blood-stages. In *P. vivax* sporozoites, the ATATTTH motif is associated with a number of
433 highly transcribed genes, including *lisp1* and *uis2-4*, known to be regulated by AP2-L in *P.*
434 *berghei* [60] as well as many of the most highly transcribed, H3K9ac marked genes, including
435 two *etramps* (PVX_086815 and PVX_088870), several RNA-binding proteins, including
436 *Puf2*, *ddx5* and a dead-box helicase (PVX_123240), as well as one of the putative *bax1*
437 inhibitors (PVX_101315). Interestingly, a number of highly transcribed and translationally
438 repressed genes associated with the ATATTTH motif, including *uis4*, *siap2* and *pv1*, are not
439 stably marked by H3K9ac in all replicates (i.e., there is significant variation in the placement
440 of the H3K9ac peak or their presence/absence among replicates for these genes). It may be
441 that additional histone modifications, for example H3K27me or H2 or H4 modifications, are
442 involved in regulating transcription of these genes. Certainly H2A.Z, which is present in *P.*

443 *falciparum*, and controls temperature responses in plants [61] is intriguing as a potential mark
444 regulating sporozoite fate in *P. vivax* considering the association between hypnozoite
445 activation rate and climate [11].

446

447 **Conclusions**

448 We provide the first comprehensive study of the transcriptome, proteome and epigenome of
449 infectious *Plasmodium vivax* sporozoites and the only study to integrate ‘omics investigation
450 of the sporozoite of any *Plasmodium* species. These data support the proposal that the
451 sporozoite is a highly-programmed stage that is primed for invasion of and development in
452 the host hepatocyte. Translational repression clearly plays a major role in shaping this stage,
453 with many of the genes proposed here as being under translational repression are involved in
454 hepatocyte infection and early liver-stage development. We highlight a major role for RNA-
455 binding proteins, including PUF2, ALBA2/4 and, intriguingly, ‘Homologue of Musashi’
456 (HoMu). Noting that HoMu uses translational repression to regulate, in *Drosophila*, stem cell,
457 and, in *Plasmodium*, gametocyte differentiation, it is intriguing to contemplate its potential
458 role in setting liver-stage developmental fate. Identifying the sporozoite transcripts regulated
459 by HoMu and other RNA binding proteins should be a key priority. As should in-depth
460 comparative analysis using similar approaches of differences between/among relapsing and
461 non-relapsing *Plasmodium* species, as well as, *P. vivax* field isolates with distinct, hypnozoite
462 phenotypes. Our study provides a key foundation for understanding the early stages of
463 hepatocyte infection and the developmental switch between liver trophozoite and hypnozoite
464 formation. Importantly, it is a major first step in rationally prioritizing targets underpinning
465 liver-stage differentiation for functional evaluation in humanized mouse and simian models
466 for relapsing *Plasmodium* species and identifying novel avenues to understand and eradicate
467 liver-stage infections.

468

469 **Methods**

470 **Material collection, isolation and preparation**

471 Nine field isolates (PvSpz-Thai 1 to 9), representing symptomatic blood-stage malaria
472 infections were collected as venous blood (20 mL) from patients presenting at malaria clinics
473 in Tak and Ubon Ratchatani provinces in Thailand. Each isolate was used to establish,
474 infections in *Anopheles dirus* colonized at Mahidol University (Bangkok) by membrane
475 feeding [13], after 14-16 days post blood feeding, ~3-15 million sporozoites were harvested
476 per field isolate from the salivary glands of up to 1,000 of these mosquitoes as per [62] and
477 shipped in preservative (trizol (RNA/DNA) or 1% paraformaldehyde (DNA for ChiP-seq)) to
478 the Walter and Eliza Hall Institute (WEHI).

479

480 **Transcriptomics sequencing and differential analysis**

481 Upon arrival at WEHI, messenger RNAs were purified from an aliquot (~0.5-1 million
482 sporozoites) of each *P. vivax* field isolate as per [29] and subjected to RNA-seq on Illumina
483 NextSeq using TruSeq library construction chemistry as per the manufacturer’s instructions.
484 Raw reads for each RNA-seq replicate are available through the Sequence Read Archive
485 (XXX-XXX). Sequencing adaptors were removed and low quality reads trimmed and filtered
486 using Trimmomatic v. 0.36 [63]. To remove host contaminants, processed reads were aligned,
487 as single-end reads, to the *Anopheles dirus* wrari2 genome (VectorBase version W1) using
488 Bowtie2[64] (--very-sensitive preset). All non-host reads were then aligned to the manually
489 curated transcripts of the *P. vivax* P01 genome
490 (<http://www.genedb.org/Homepage/PvivaxP01>) using RSEM [65] (pertinent settings: --
491 bowtie2 --bowtie2-sensitivity-level very_sensitive --calc-ci --ci-memory 10240 --estimate-
492 rspd --paired-end). Transcript abundance for each gene in each replicate was calculated by
493 RSEM as raw count, posterior mean estimate expected counts (pme-EC) and transcripts per
494 million (TPM).

495 Transcriptional abundance in *P. vivax* sporozoites was compared qualitatively (by
496 ranked abundance) with previously published microarray data for *P. vivax* salivary-gland
497 sporozoites [23]. As a further quality control, these RNA-seq data were compared also with

498 previously published microarray data for *P. falciparum* salivary-gland sporozoites [26], as
499 well as RNA-seq data from salivary-gland sporozoites generated here for *P. falciparum*
500 (single replicate generated from *P. falciparum* 3D7 lab cultures isolated from *Anopheles*
501 *stephensi* and processed as above) and previously published for *P. yoelii* [25]. RNA-seq data
502 from these additional *Plasmodium* species were (re)analysed from raw reads and
503 transcriptional abundance for each species was determined (raw counts and pme-EC and TPM
504 data) as described above using gene models current as of 04-10-2016 (PlasmoDB release
505 v29). Interspecific transcriptional behaviour was qualitatively compared by relative ranked
506 abundance in each species using TPM data for single copy orthologs (SCOs; defined in
507 PlasmoDB) only, shared between *P. vivax* and *P. falciparum* or shared among *P. vivax*, *P.*
508 *falciparum* and *P. yoelii*.

509 To define sporozoite-enriched transcripts, we remapped raw reads representing early
510 (18-24 hours post-infection (HPI)), mid (30-40 HPI) and late (42-46 HPI) *P. vivax* blood-
511 stage infections recently published by Zhu *et al* [29] to the *P. vivax* P01 transcripts using
512 RSEM as above. All replicate data was assessed for mapping metrics, transcript saturation
513 and other standard QC metrics using QualiMap v 2.1.3 [66]. Differential transcription
514 between *P. vivax* salivary-gland sporozoites and mixed blood-stages [29] was assessed using
515 pme-EC data in EdgeR [67] (differential transcription cut-off: ≥ 2 -fold change in counts per
516 million (CPM) and a False Discovery Rate (FDR) ≤ 0.05). Pearson Chi squared tests were
517 used to detect over-represented Pfam domains and Gene Ontology (GO) terms among
518 differentially transcribed genes in sporozoites (Bonferroni-corrected $p < 0.05$), based on gene
519 annotations in PlasmoDB (release v29).

520

521 **Proteomic sequencing and quantitative analysis**

522 Aliquots of $\sim 10^7$ salivary-gland sporozoites were generated from PvSpz-Thai1 and PvSpz-
523 Thai6 isolates, purified on an Accudenz gradient per [62] and shipped on dry ice (protein) to
524 the Center for Infectious Disease Research (CIDR). These cells were lysed in 2x Sample
525 Buffer and their proteins separated by SDS-PAGE per [40]. For the whole proteome analysis,
526 each gel was run out 52 mm and cut into 27-29 fractions using a grid cutter (Gel Company,
527 San Francisco, CA). Pooled peptides in each gel fraction were reduced in dithiothreitol /
528 ammonium bicarbonate, and digested for 4.5 hours at 36 °C in 6.25 ng/mL trypsin under
529 vortex at 700 RPM. The supernatant was recovered and peptides were extracted by incubating
530 the gel in 2% (v/v) acetonitrile/1% (v/v) formic acid. Supernatant after three extractions was
531 combined with the digest supernatant, evaporated to dryness in a rotary vacuum, and
532 reconstituted in HPLC loading buffer consisting of 2% (v/v) acetonitrile/0.2% (v/v)
533 trifluoroacetic acid. Nanoflow liquid chromatography (nanoLC) was performed using an
534 Agilent 1100 nano pump with electronically controlled split flow or a Proxeon Easy nLC.
535 Peptides were separated on a column with an integrated fritted tip (360 μm outer diameter
536 (O.D.), 75 μm inner diameter (I.D.), 15 μm I.D. tip; New Objective) packed in-house with a
537 20 cm bed of C18 (Dr. Maisch ReproSil-Pur C18-AQ, 120 Å, 3 μm ; Ammerbuch-Entringen,
538 Germany). Tandem mass spectrometry (MS/MS) was performed with an LTQ Velos Pro-
539 Orbitrap Elite (Thermo Fisher Scientific). Two nanoLC-MS technical replicates were
540 performed for each fraction, with roughly half the available sample injected for each
541 replicate. The mass spectrometry data generated for this manuscript, along with the search
542 parameters, analysis parameters and protein databases can be downloaded from PeptideAtlas
543 (www.peptideatlas.org) using the identifier #####.

544 Mass spectrometer output files were converted to .mZML format using MSConvert
545 version 2.2.0 (whole proteome data) or 3.0.5533 (surface-labeled data) [68] and searched with
546 X!Tandem [69] version 2013.06.15.1 JACKHAMMER and Comet version 2015.02 rev.0.[70]
547 MS/MS data were analyzed using the Trans-Proteomic Pipeline[71] version 4.8.0 PHILAE.
548 Peptide spectrum matches (PSM) generated by each search engine were analyzed separately
549 with PeptideProphet [72] and combined in iProphet.[73] Protein identifications were inferred
550 with ProteinProphet [74]. In the case that multiple proteins were inferred at equal confidence
551 by a set of peptides, the inference was counted as a single identification and all relevant
552 protein IDs were listed. Only proteins with ProteinProphet probabilities corresponding to a

553 model-estimated false discovery rate (FDR) less than 1.0 % were reported. Spectra were
554 searched against a protein sequence database comprised of *P. vivax* P01 (version 29,
555 www.plasmodb.org), *An. stephensi* SDA 500 (version 1.3, www.vectorbase.org), and a
556 modified version of the common Repository of Adventitious Proteins (version 2012.01.01,
557 www.thegpm.org/cRAP) with the Sigma Universal Standard Proteins removed and the LC
558 calibration standard peptide [Glu-1] fibrinopeptide B appended. Label-free proteomics
559 methods based on spectral counts (SpC) were used to identify proteins that were significantly
560 more abundant in labeled samples compared to unlabeled controls. The SpC for a given
561 protein in a given biological replicate was taken as the number of PSM used by
562 ProteinProphet to make the protein inference. All SpC values were increased by one in order
563 to give all proteins non-zero SpC values for log-transformation [75]. The spectral abundance
564 factor (SAF) for a given protein was calculated as the quotient of the SpC and the protein's
565 length and natural log-transformed to $\ln(\text{SAF})$ [76]. For a more detailed description of the
566 proteome data collection process and analysis please refer to manuscript by Swearingen *et al*
567 (*submitted*).

568 To identify genes likely under translational repression in the *P. vivax* sporozoite, we
569 examined these data for genes that were highly transcribed (top 10 percentile) but for which
570 we could find no evidence of protein expression in any sporozoite replicate. In addition, we
571 conducted abundance ranked comparisons between the mean transcriptional abundance of
572 each *P. vivax* gene in sporozoites (see above) and the mean quantitative abundance of its
573 protein in our expressional data. Genes were sorted on the differential between their relative
574 transcription and relative expression ranking to identify highly transcribed genes with
575 substantially lower expression relative to their transcriptional abundance.

576

577 **Salivary-gland sporozoite and liver-stage immunofluorescence assays (IFAs)**

578 IFAs were performed as per [13]. Liver stages were obtained from 10 μ m formalin fixed
579 paraffin embedded day 7 liver stages generated previously [13] from FRG knockout huHep
580 mice; [13] these were deparaffinized prior to staining. Fresh salivary-gland sporozoites were
581 fixed in acetone per [13]. All cells were incubated twice for 3 minutes in Xylene, then 100%
582 Ethanol, and finally once for 3 minutes each in 95%, 70%, and 50% Ethanol. The cells were
583 rinsed in DI water and permeabilized immediately in 1XTBS, containing Triton X-100 and
584 30% hydrogen peroxide. The cells were blocked in 5% milk in 1XTBS. The hepatocytes were
585 stained overnight with a rabbit polyclonal LISP1 antibody (A), a rabbit polyclonal UIS4
586 antibody (B), and a rabbit polyclonal BIP antibody (C) in blocking buffer. The cells were
587 washed with 1XTBS and the primary antibodies were detected with goat anti-rabbit Alexa
588 Fluor 488 antibody (Life Technologies). The cells were washed in 1XTBS. The hepatocytes
589 were rinsed in KMNO₄ and washed in 1XTBS. The cells were incubated in DAPI for 5
590 minutes.

591

592 **Histone ChIP sequencing and analysis**

593 Aliquots of 2 – 6 million freshly isolated sporozoites were fixed with 1% paraformaldehyde
594 for 10 min at 37°C and the reaction subsequently quenched by adding glycine to a final
595 concentration of 125 mM. After three washes with PBS, sporozoite pellets were stored at -
596 80°C and shipped to Australia. Nuclei were released from the sporozoites by dounce
597 homogenization in lysis buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
598 EDTA, 1 mM DTT, 1x EDTA-free protease inhibitor cocktail (Roche), 0.25% NP40). Nuclei
599 were pelleted by centrifugation at 21,000 g for 10 min at 4°C and resuspended in SDS lysis
600 buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8.1, 1x EDTA-free protease inhibitor
601 cocktail). Chromatin was sheared into 200–1000 bp fragments by sonication for 16 cycles in
602 30 sec intervals (on/off, high setting) using a Bioruptor (Diagenode) and diluted 1:10 in ChIP
603 dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.1, 150
604 mM NaCl). Chromatin was precleared for 1 hour with protein A/G sepharose (4FastFlow, GE
605 Healthcare) equilibrated in 0.1% BSA in ChIP dilution buffer. Chromatin from 3 x 10⁵ nuclei
606 was taken aside as input material. Chromatin from approximately 3 x 10⁶ sporozoite nuclei
607 was used for each ChIP. ChIP was carried out over night at 4°C with 5 μ g of antibody

608 (H3K9me3 (Active Motif), H3K4me3 (Abcam), H3K9ac (Upstate), H4K16ac (Abcam)) and
609 10 μ l each of equilibrated protein A and G sepharose beads (4FastFlow, GE Healthcare).
610 After washes in low-salt, high-salt, LiCl, and TE buffers (EZ-ChIP Kit, Millipore),
611 precipitated complexes were eluted in 1% SDS, 0.1 M NaHCO₃. Cross-linking of the immune
612 complexes and input material was reversed for 6 hours at 45°C after addition of 500 mM
613 NaCl and 20 μ g/ml of proteinase K (NEB). DNA was purified using the MinElute® PCR
614 purification kit (Qiagen) and paired-end sequenced on Illumina NextSeq using TruSeq library
615 construction chemistry as per the manufacturer's instructions. Raw reads for each ChIP-seq
616 replicate are available through the Sequence Read Archive (XXX-XXX).
617 Fastq files were checked for quality using fastqc
618 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) and adapter sequences were
619 trimmed using cutadapt [77]. Paired end reads were mapped to the *P. vivax* P01 strain
620 genome annotation using Bowtie2 [64]. The alignment files were converted to Bam format,
621 sorted and indexed using Samtools [78]. ChIP peaks were called relative to input using
622 MACS2[79] in paired end mode with a q value less than or equal to 0.01. Peaks and peak
623 summits were converted to sorted BED files. Bedtools intersect[80] was used to identify
624 genes that intersected H3K9me3 peaks and Bedtools closest was used to identify genes that
625 were closest to and downstream of H3K9ac and H3K4me3 peak summits.
626

627 **Sequence motif analysis**

628 Conserved sequence motifs were identified using the program DREME [81]. Only genes in
629 the top decile of transcription showing no evidence of protein expression in multiple salivary-
630 gland sporozoite replicates were considered as putatively translationally repressed (n = 170).
631 We queried coding regions and regions upstream of the transcriptional start site (TSS) for
632 each gene, defined by Zhu *et al* [29] and/or predicted here from all RNA-seq data using the
633 Tuxedo suite [82], for enriched sequence motifs in comparison to 170 genes found to be in
634 the top decile of both transcriptional and expressional abundance in the same sporozoite
635 replicates. In searching for motifs associated with highly transcribed genes with stable
636 H3K9ac marks within 1kb of the TSS (or up to the 3' end of the next gene upstream), we
637 compared H3K9ac marked genes in the top decile of transcription to the same number of
638 H3K9ac marked genes in the bottom decile of transcription. In both instances, an e-value
639 threshold of 0.05 was considered the minimum threshold for statistical significance.
640

641 **Author contributions:** Study design and development: Ivo Muller^{1,2,3} (IM), Aaron R. Jex^{1,3,4}
642 (AJ), Stefan H. I. Kappe⁵ (SK) and Sebastian A. Mikolajczak⁵ (SM); Parasite collection and
643 sporozoite production and purification: Jetsumon Sattabongkot⁷ (JSP), Rapatbhorn
644 Patrapuvich⁶ (RP), SK, SM, Scott Lindner⁸ (SL) and Erika L. Flannery⁵ (EF); DNA/RNA
645 isolation and sequence library preparation: Cristian Koepfli¹ (CK) and EF; Transcriptomics
646 analysis: AJ, Brendan Ansell⁴ (BA) and Anita Lerch¹ (AL); Proteomics analysis: Kristian
647 Swearingen⁵ (KS), Robert Moritz (RM)⁹ SL, SM and EF; ChIP-seq preparation and analyses:
648 Michaela Petter¹⁰ (MP) and Michael Duffy¹⁰ (MD); Immunofluorescence assays: Vorada
649 Chuenchob⁵; Data integration and interpretation: AJ, IM, EF, SM and SK; Manuscript
650 preparation: AJ, IM, SM, SK, SL, and EF.
651

652 **Author affiliations:** 1. Population Health and Immunity Division, The Walter and Eliza Hall
653 Institute for Medical Research, 1G Royal Parade, Parkville, Victoria, 3052, Australia; 2.
654 Malaria: Parasites & Hosts Unit, Institut Pasteur, 28 Rue de Dr. Roux, 75015, Paris, France;
655 3. Department of Medical Biology, The University of Melbourne, Victoria, 3010, Australia;
656 4. Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Corner of
657 Park and Flemington Road, Parkville, Victoria, 3010, Australia; 5. Center for Infectious
658 Disease Research, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109, USA; 6.
659 Department of Global Health, University of Washington, Seattle, WA 98195, USA; 7.
660 Mahidol Vivax Research Center, Faculty of Tropical Medicine, Mahidol University, Bangkok
661 10400, Thailand; 8. Department of Biochemistry and Molecular Biology, Center for Malaria
662 Research, Pennsylvania State University, University Park, PA 16802, USA. 9. Institute for

663 Systems Biology, Seattle, WA, 98109, USA. 10. Department of Medicine Royal Melbourne
664 Hospital, The Peter Doherty Institute, The University of Melbourne, 792 Elizabeth Street,
665 Melbourne, Victoria 3000, Australia. 11. Institute of Microbiology, University Hospital
666 Erlangen, Erlangen 91054, Germany.

667

668 **Acknowledgements:** The authors acknowledge funding from the National Health and
669 Medical Research Council (NHMRC, APP1021544, 1043345, & 1092789), the Australian
670 Research Council (ARC), the Victorian State Government Operational Infrastructure Support
671 and Australian Government National Health and Medical Research Council Independent
672 Research Institute Infrastructure Support Scheme, the Ian Potter Foundation, the National
673 Institute of Health, the Bill and Melinda Gates Foundation, the US Department of Defense
674 (W81XWH-15-1-0249) and the Office of the Assistant Secretary of Defence for Health
675 Affairs through the Peer Reviewed Medical Research Program (PRMRP).

676

677 **Competing Interests:** The authors declare that no author of this manuscript has a competing
678 financial or non-financial interest related to this work.

679

680

681 References

- 682 1. Organization WH: World Malaria Report 2015. WHO, Geneva. 2015.
- 683 2. Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, Greenwood BM, et al:
684 Shrinking the malaria map: progress and prospects. *Lancet*.
685 2010;376(9752):1566-78.
- 686 3. Price RN, Douglas NM, Anstey NM: New developments in *Plasmodium vivax*
687 malaria: severe disease and the rise of chloroquine resistance. *Curr Opin Infect*
688 *Dis*. 2009;22(5):430-5.
- 689 4. Baird KJ: Malaria caused by *Plasmodium vivax*: recurrent, difficult to treat,
690 disabling, and threatening to life - averting the infectious bite preempts these
691 hazards. *Pathogens Global Health*. 2013;107475-9.
- 692 5. Sattabongkot J, Tsuboi T, Zollner GE, Sirichaisinthop J, Cui L: *Plasmodium vivax*
693 transmission: chances for control? *Trends Parasitol*. 2004;20(4):192-8.
- 694 6. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, et al: Key gaps
695 in the knowledge of *Plasmodium vivax*, a neglected human malaria parasite.
696 *Lancet Infect Dis*. 2009;9(9):555-66.
- 697 7. Lindner SE, Miller JL, Kappe SH: Malaria parasite pre-erythrocytic infection:
698 preparation meets opportunity. *Cell Microbiol*. 2012;14(3):316-24.
- 699 8. Mota MM, Pradel G, Vanderberg JP, Hafalla JC, Frevert U, Nussenzweig RS, et al:
700 Migration of *Plasmodium* sporozoites through cells before infection. *Science*.
701 2001;291(5501):141-4.
- 702 9. Shin SC, Vanderberg JP, Terzakis JA: Direct infection of hepatocytes by
703 sporozoites of *Plasmodium berghei*. *J Protozool*. 1982;29(3):448-54.
- 704 10. Lysenko AJ, Beljaev A, Rybalka V: Population studies of *Plasmodium vivax*: 1. The
705 theory of polymorphism of sporozoites and epidemiological phenomena of
706 tertian malaria. *Bulletin WHO*. 1977;55(5):541.
- 707 11. White NJ: Determinants of relapse periodicity in *Plasmodium vivax* malaria.
708 *Malar J*. 2011;10297.
- 709 12. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM: Vivax malaria:
710 neglected and not benign. *Amer J Trop Med Hyg*. 2007;77(6 Suppl):79-87.
- 711 13. Mikolajczak SA, Vaughan AM, Kangwanrangsan N, Roobsoong W, Fishbaugher M,
712 Yimamnuaychok N, et al: *Plasmodium vivax* liver stage development and
713 hypnozoite persistence in human liver-chimeric mice. *Cell Host Microbe*.
714 2015;17(4):526-35.

- 715 14. Mueller A-K, Camargo N, Kaiser K, Andorfer C, Frevert U, Matuschewski K, et al:
716 *Plasmodium* liver stage developmental arrest by depletion of a protein at the
717 parasite–host interface. *Proc Natl Acad Sci U S A*. 2005;102(8):3022-7.
- 718 15. Silvie O, Briquet S, Muller K, Manzoni G, Matuschewski K: Post-transcriptional
719 silencing of UIS4 in *Plasmodium berghei* sporozoites is important for host switch.
720 *Mol Microbiol*. 2014;91(6):1200-13.
- 721 16. Mackellar DC, O'Neill MT, Aly AS, Sacci JB, Jr., Cowman AF, Kappe SH:
722 *Plasmodium falciparum* PF10_0164 (ETRAMP10.3) is an essential
723 parasitophorous vacuole and exported protein in blood stages. *Eukaryot Cell*.
724 2010;9(5):784-94.
- 725 17. Demele L, Franetich JF, Lorthiois A, Gego A, Zeeman AM, Kocken CH, et al:
726 Persistence and activation of malaria hypnozoites in long-term primary
727 hepatocyte cultures. *Nat Med*. 2014;20(3):307-12.
- 728 18. Malmquist NA, Moss TA, Mecheri S, Scherf A, Fuchter MJ: Small-molecule histone
729 methyltransferase inhibitors display rapid antimalarial activity against all blood
730 stage forms in *Plasmodium falciparum*. *Proc Natl Acad Sci U S A*.
731 2012;109(41):16708-13.
- 732 19. Josling GA, Llinas M: Sexual development in *Plasmodium* parasites: knowing
733 when it's time to commit. *Nat Rev Microbiol*. 2015;13(9):573-87.
- 734 20. White MT, Karl S, Battle KE, Hay SI, Mueller I, Ghani AC: Modelling the
735 contribution of the hypnozoite reservoir to *Plasmodium vivax* transmission. *Elife*.
736 2014;3.
- 737 21. Roobsoong W, Tharinjaroen CS, Rachaphaew N, Chobson P, Schofield L, Cui L, et
738 al: Improvement of culture conditions for long-term in vitro culture of
739 *Plasmodium vivax*. *Malaria J*. 2015;14(1):1.
- 740 22. Cubi R, Vembar SS, Biton A, Franetich JF, Bordessoulles M, Sossau D, et al: Laser
741 capture microdissection enables transcriptomic analysis of dividing and
742 quiescent liver stages of *Plasmodium* relapsing species. *Cell Microbiol*. 2017.
- 743 23. Westenberger SJ, McClean CM, Chattopadhyay R, Dharia NV, Carlton JM,
744 Barnwell JW, et al: A systems-based analysis of *Plasmodium vivax* lifecycle
745 transcription from human to mosquito. *PLoS Negl Trop Dis*. 2010;4(4):e653.
- 746 24. Gomez-Diaz E, Yerbanga RS, Lefevre T, Cohuet A, Rowley MJ, Ouedraogo JB, et al:
747 Epigenetic regulation of *Plasmodium falciparum* clonally variant gene expression
748 during development in *Anopheles gambiae*. *Sci Rep*. 2017;740655.
- 749 25. Lindner SE, Mikolajczak SA, Vaughan AM, Moon W, Joyce BR, Sullivan WJ, Jr., et
750 al: Perturbations of *Plasmodium* Puf2 expression and RNA-seq of Puf2-deficient
751 sporozoites reveal a critical role in maintaining RNA homeostasis and parasite
752 transmissibility. *Cell Microbiol*. 2013;15(7):1266-83.
- 753 26. Le Roch KG, Johnson JR, Florens L, Zhou Y, Santrosyan A, Grainger M, et al: Global
754 analysis of transcript and protein levels across the *Plasmodium falciparum* life
755 cycle. *Genome Res*. 2004;14(11):2308-18.
- 756 27. Mikolajczak SA, Silva-Rivera H, Peng X, Tarun AS, Camargo N, Jacobs-Lorena V, et
757 al: Distinct malaria parasite sporozoites reveal transcriptional changes that
758 cause differential tissue infection competence in the mosquito vector and
759 mammalian host. *Mol Cell Biol*. 2008;28(20):6196-207.
- 760 28. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, et al: Comparative
761 genomics of the neglected human malaria parasite *Plasmodium vivax*. *Nature*.
762 2008;455(7214):757-63.
- 763 29. Zhu L, Mok S, Imwong M, Jaidee A, Russell B, Nosten F, et al: New insights into
764 the *Plasmodium vivax* transcriptome using RNA-Seq. *Sci Rep*. 2016;620498.
- 765 30. Kramer S: RNA in development: how ribonucleoprotein granules regulate the life
766 cycles of pathogenic protozoa. *WIR: RNA*. 2014;5(2):263-84.
- 767 31. Tucker RP: The thrombospondin type 1 repeat superfamily. *Int J Biochem Cell*
768 *Biol*. 2004;36(6):969-74.

- 769 32. Ntumngia FB, Bouyou-Akotet MK, Uhlemann AC, Mordmuller B, Kremsner PG,
770 Kun JF: Characterisation of a tryptophan-rich *Plasmodium falciparum* antigen
771 associated with merozoites. *Mol Biochem Parasitol.* 2004;137(2):349-53.
- 772 33. Gubbels MJ, Vaishnava S, Boot N, Dubremetz JF, Striepen B: A MORN-repeat
773 protein is a dynamic component of the *Toxoplasma gondii* cell division
774 apparatus. *J Cell Sci.* 2006;119(Pt 11):2236-45.
- 775 34. Aly AS, Lindner SE, MacKellar DC, Peng X, Kappe SH: SAP1 is a critical post-
776 transcriptional regulator of infectivity in malaria parasite sporozoite stages. *Mol*
777 *Microbiol.* 2011;79(4):929-39.
- 778 35. Okano H, Imai T, Okabe M: Musashi: a translational regulator of cell fate. *J Cell*
779 *Sci.* 2002;115(7):1355-9.
- 780 36. Cui L, Lindner S, Miao J: Translational regulation during stage transitions in
781 malaria parasites. *Annals N Y Acad Sci.* 2015;1342(1):1-9.
- 782 37. Lasko P: Gene regulation at the RNA layer: RNA binding proteins in intercellular
783 signaling networks. *Sci STKE.* 2003;179RE6.
- 784 38. Guerreiro A, Deligianni E, Santos JM, Silva PA, Louis C, Pain A, et al: Genome-wide
785 RIP-Chip analysis of translational repressor-bound mRNAs in the *Plasmodium*
786 gametocyte. *Genome Biol.* 2014;15(11):493.
- 787 39. Kappe SH, Buscaglia CA, Bergman LW, Coppens I, Nussenzweig V: Apicomplexan
788 gliding motility and host cell invasion: overhauling the motor model. *Trends in*
789 *parasitology.* 2004;20(1):13-6.
- 790 40. Lindner SE, Swearingen KE, Harupa A, Vaughan AM, Sinnis P, Moritz RL, et al:
791 Total and putative surface proteomics of malaria parasite salivary gland
792 sporozoites. *Mol Cell Proteomics.* 2013;12(5):1127-43.
- 793 41. Silvie O, Briquet S, Müller K, Manzoni G, Matuschewski K: Post-transcriptional
794 silencing of UIS4 in *Plasmodium berghei* sporozoites is important for host switch.
795 *Molecular microbiology.* 2014;91(6):1200-13.
- 796 42. Kelley KD, Miller KR, Todd A, Kelley AR, Tuttle R, Berberich SJ: YPEL3, a p53-
797 regulated gene that induces cellular senescence. *Cancer Res.* 2010;70(9):3566-
798 75.
- 799 43. Tuttle R, Simon M, Hitch DC, Maiorano JN, Hellan M, Ouellette J, et al:
800 Senescence-associated gene YPEL3 is downregulated in human colon tumors.
801 *Ann Surg Oncol.* 2011;18(6):1791-6.
- 802 44. Struck NS, de Souza Dias S, Langer C, Marti M, Pearce JA, Cowman AF, et al: Re-
803 defining the Golgi complex in *Plasmodium falciparum* using the novel Golgi
804 marker PfGRASP. *J Cell Sci.* 2005;118(Pt 23):5603-13.
- 805 45. Graewe S, Stanway RR, Rennenberg A, Heussler VT: Chronicle of a death
806 foretold: *Plasmodium* liver stage parasites decide on the fate of the host cell.
807 *FEMS Microbiol Rev.* 2012;36(1):111-30.
- 808 46. Bruchhaus I, Roeder T, Rennenberg A, Heussler VT: Protozoan parasites:
809 programmed cell death as a mechanism of parasitism. *Trends Parasitol.*
810 2007;23(8):376-83.
- 811 47. Albuquerque SS, Carret C, Grosso AR, Tarun AS, Peng X, Kappe SH, et al: Host cell
812 transcriptional profiling during malaria liver stage infection reveals a
813 coordinated and sequential set of biological events. *BMC genomics.*
814 2009;10(1):1.
- 815 48. Kaushansky A, Metzger PG, Douglass AN, Mikolajczak SA, Lakshmanan V, Kain
816 HS, et al: Malaria parasite liver stages render host hepatocytes susceptible to
817 mitochondria-initiated apoptosis. *Cell Death Dis.* 2013;4e762.
- 818 49. Liu M, Miao J, Liu T, Sullivan WJ, Cui L, Chen X: Characterization of TgPuf1, a
819 member of the Puf family RNA-binding proteins from *Toxoplasma gondii*.
820 *Parasites & vectors.* 2014;7(1):1.

- 821 50. Miao J, Fan Q, Parker D, Li X, Li J, Cui L: Puf mediates translation repression of
822 transmission-blocking vaccine candidates in malaria parasites. *PLoS Pathog.*
823 2013;9(4):e1003268.
- 824 51. Yuda M, Iwanaga S, Shigenobu S, Kato T, Kaneko I: Transcription factor AP2-Sp
825 and its target genes in malarial sporozoites. *Mol Microbiol.* 2010;75(4):854-63.
- 826 52. Lopez-Rubio J-J, Mancio-Silva L, Scherf A: Genome-wide analysis of
827 heterochromatin associates clonally variant gene regulation with perinuclear
828 repressive centers in malaria parasites. *Cell Host Microbe.* 2009;5(2):179-90.
- 829 53. Duffy MF, Selvarajah SA, Josling GA, Petter M: Epigenetic regulation of the
830 *Plasmodium falciparum* genome. *Brief Funct Genomics.* 2014;13(3):203-16.
- 831 54. Cui L, Miao J, Furuya T, Li X, Su XZ, Cui L: PfGCN5-mediated histone H3
832 acetylation plays a key role in gene expression in *Plasmodium falciparum*.
833 *Eukaryot Cell.* 2007;6(7):1219-27.
- 834 55. Guizetti J, Scherf A: Silence, activate, poise and switch! Mechanisms of antigenic
835 variation in *Plasmodium falciparum*. *Cell Microbiol.* 2013;15(5):718-26.
- 836 56. Rovira-Graells N, Gupta AP, Planet E, Crowley VM, Mok S, de Pouplana LR, et al:
837 Transcriptional variation in the malaria parasite *Plasmodium falciparum*.
838 *Genome Res.* 2012;22(5):925-38.
- 839 57. De Silva EK, Gehrke AR, Olszewski K, León I, Chahal JS, Bulyk ML, et al: Specific
840 DNA-binding by apicomplexan AP2 transcription factors. *Proc Natl Acad Sci U S*
841 *A.* 2008;105(24):8393-8.
- 842 58. Painter HJ, Campbell TL, Llinás M: The Apicomplexan AP2 family: integral factors
843 regulating *Plasmodium* development. *Mol Biochem Parasitol.* 2011;176(1):1-7.
- 844 59. Kafsack BF, Rovira-Graells N, Clark TG, Bancells C, Crowley VM, Campino SG, et
845 al: A transcriptional switch underlies commitment to sexual development in
846 human malaria parasites. *Nature.* 2014;507(7491):248.
- 847 60. Iwanaga S, Kaneko I, Kato T, Yuda M: Identification of an AP2-family protein that
848 is critical for malaria liver stage development. *PLoS One.* 2012;7(11):e47557.
- 849 61. Boden SA, Kavanova M, Finnegan EJ, Wigge PA: Thermal stress effects on grain
850 yield in *Brachypodium distachyon* occur via H2A.Z-nucleosomes. *Genome Biol.*
851 2013;14(6):R65.
- 852 62. Kennedy M, Fishbaugher ME, Vaughan AM, Patrapuvich R, Boonhok R,
853 Yimamnuaychok N, et al: A rapid and scalable density gradient purification
854 method for *Plasmodium* sporozoites. *Malar J.* 2012;11:421.
- 855 63. Bolger AM, Lohse M, Usadel B: Trimmomatic: a flexible trimmer for Illumina
856 sequence data. *Bioinformatics.* 2014;30(15):2114-20.
- 857 64. Langmead B, Salzberg SL: Fast gapped-read alignment with Bowtie 2. *Nat*
858 *Methods.* 2012;9(4):357-9.
- 859 65. Li B, Dewey CN: RSEM: accurate transcript quantification from RNA-Seq data
860 with or without a reference genome. *BMC Bioinformatics.* 2011;12(1):323.
- 861 66. Okonechnikov K, Conesa A, Garcia-Alcalde F: Qualimap 2: advanced multi-
862 sample quality control for high-throughput sequencing data. *Bioinformatics.*
863 2016;32(2):292-4.
- 864 67. Nikolayeva O, Robinson MD: edgeR for differential RNA-seq and ChIP-seq
865 analysis: an application to stem cell biology. *Methods Mol Biol.* 2014;115045-79.
- 866 68. Kessner D, Chambers M, Burke R, Agus D, Mallick P: ProteoWizard: open source
867 software for rapid proteomics tools development. *Bioinformatics.*
868 2008;24(21):2534-6.
- 869 69. Craig R, Beavis RC: TANDEM: matching proteins with tandem mass spectra.
870 *Bioinformatics.* 2004;20(9):1466-7.
- 871 70. Eng JK, Jahan TA, Hoopmann MR: Comet: an open-source MS/MS sequence
872 database search tool. *Proteomics.* 2013;13(1):22-4.


- 873 71. Deutsch EW, Mendoza L, Shteynberg D, Slagel J, Sun Z, Moritz RL: Trans-
874 Proteomic Pipeline, a standardized data processing pipeline for large-scale
875 reproducible proteomics informatics. *Proteomics Clin Appl.* 2015;9(7-8):745-54.
876 72. Keller A, Nesvizhskii AI, Kolker E, Aebersold R: Empirical statistical model to
877 estimate the accuracy of peptide identifications made by MS/MS and database
878 search. *Anal Chem.* 2002;74(20):5383-92.
879 73. Shteynberg D, Deutsch EW, Lam H, Eng JK, Sun Z, Tasman N, et al: iProphet:
880 multi-level integrative analysis of shotgun proteomic data improves peptide and
881 protein identification rates and error estimates. *Mol Cell Proteomics.*
882 2011;10(12):M111 007690.
883 74. Nesvizhskii AI, Keller A, Kolker E, Aebersold R: A statistical model for identifying
884 proteins by tandem mass spectrometry. *Anal Chem.* 2003;75(17):4646-58.
885 75. Hendrickson EL, Xia Q, Wang T, Leigh JA, Hackett M: Comparison of spectral
886 counting and metabolic stable isotope labeling for use with quantitative
887 microbial proteomics. *Analyst.* 2006;131(12):1335-41.
888 76. Zybailov B, Mosley AL, Sardu ME, Coleman MK, Florens L, Washburn MP:
889 Statistical analysis of membrane proteome expression changes in
890 *Saccharomyces cerevisiae*. *J Proteome Res.* 2006;5(9):2339-47.
891 77. Martin M: Cutadapt removes adapter sequences from high-throughput
892 sequencing reads. *EMBnet journal.* 2011;17(1):pp. 10-2.
893 78. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al: The Sequence
894 Alignment/Map format and SAMtools. *Bioinformatics.* 2009;25(16):2078-9.
895 79. Zhang Y, Liu T, Meyer CA, Eeckhoutte J, Johnson DS, Bernstein BE, et al: Model-
896 based analysis of ChIP-Seq (MACS). *Genome Biol.* 2008;9(9):R137.
897 80. Quinlan AR, Hall IM: BEDTools: a flexible suite of utilities for comparing genomic
898 features. *Bioinformatics.* 2010;26(6):841-2.
899 81. Bailey TL: DREME: motif discovery in transcription factor ChIP-seq data.
900 *Bioinformatics.* 2011;27(12):1653-9.
901 82. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al: Differential gene
902 and transcript expression analysis of RNA-seq experiments with TopHat and
903 Cufflinks. *Nat Protoc.* 2012;7(3):562-78.
904
905

906 **Figures**

907

908 **Fig. 1** Differential transcription between *Plasmodium vivax* salivary-gland sporozoites
 909 and blood-stages. **a** BCV plot showing separation between blood-stage (black) and
 910 salivary-gland sporozoite (red) biological replicates. **b** Volcano plot of distribution of
 911 fold-changes (FC) in transcription between blood-stages and salivary-gland sporozoites
 912 relative to statistical significance threshold (False Discovery Rate (FDR) \leq 0.05). Positive
 913 FC represents enriched transcription in the sporozoite stage. **c** Mirror plot showing
 914 pFam domains statistically significantly (FDR \leq 0.05) over-represented in salivary-gland
 915 sporozoite enriched (red) or blood-stage enriched (black) transcripts. Scale bar
 916 truncated for presentation. * - 55 PRESAN domains are in this dataset. ** - 99 Vir
 917 domains are in this dataset.

918




919

920

921

922 **Fig. 2** Histone epigenetics relative to transcriptional behaviour in salivary-gland
 923 sporozoites. **a** Representative H3K9me³, H3K4me³ and H3K9ac ChIP-seq data (grey)
 924 from a representative chromosome (*P. vivax* P01 Chr5) relative to mRNA transcription
 925 in salivary-gland sporozoites (black) and blood-stages (black). Small numbers to top left
 926 of each row show data range. **b** Salivary-gland sporozoite transcription relative to
 927 nearest stable histone epigenetic marks. Numbers at the top of the figure represent total
 928 genes included in each category. Numbers within in box plot represent mean
 929 transcription in transcripts per million (TPM). **c** Sequence motifs enriched within 1kb
 930 upstream of the Transcription Start Site of highly transcribed (top 10%) relative to
 931 lowly transcribed genes associated with H3K9ac marks in salivary-gland sporozoites. **d**
 932 Relative transcription of (sub)telomeric genes in *P. vivax* salivary-gland sporozoites and
 933 blood-stages categorized by gene sets enriched in blood-stages (blue), salivary
 934 sporozoites (red) or not stage enriched (grey). Numbers in each box show mean
 935 transcription in TPM.
 936



937
 938

